Our results suggest that the currently applied criteria for ERBB2 overexpression in ovarian cancer (i.e. 2+ and 3+) are too restrictive and from the clinical viewpoint it would be justified to include any ERBB2 membranous expression in above 10% of the tumour cells to positivity (or overexpression). This evidence concerns the gene ERBB2 and neoplasm.